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ABSTRACT
The effect of oleic acid on losartan transdermal permeation has been observed to explore its
ability as chemical enhancer. Potassium losartan solutions in citric buffer pH 5.0 were made
in two levels of concentration i.e. 2 mg/mL and 10 mg/mL using propylene glycol 15% as
solubilizing agent. Losartan transport from such solutions with and without oleic acid one hour
pretreatment were tested using male Wistar rat skin as a membrane for 30 hours in vertical
diffusion sel. The transport profiles were analyzed based on the lag time diffusion method. It
is showed that oleic acid pretreatment did not effect on losartan permeation rate and efficiency
of 2 mg/mL potassium losartan concentration. However, such pretreatment enhanced losartan
permeation rate and efficiency 21 and 23-fold higher respectively for 10 mg/mL the potassium
losartan concentration. It is predicted that losartan minimum effective plasma concentration
can be achieved in transdermal administration through this transport improvement in normal
application area.
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INTRODUCTION
Losartan(1-((2’-(2H-tetrazol-5-il)bifenil-4-il)metil)2-butil-4-kloro-1H-imidazol-5-il)methanol) is the first
Angiotensin II Receptor Antagonist available in the
market (Ripley and Hirsch 2010). The administration
of losartan in diabetic-hypertension complication shows
a significant advantages (Murthy, Kommineni, and
Mayuren, 2013; Pan et al., 2015). Moreover, losartan
also has an ability to protect the liver against ischemia
(Koh, Yoon, and Lee, 2013).
This compound has low oral bioavailability (0.33)
(Ripley and Hirsch 2010) due to the intensive first pass
effect by CYP2C9 and CYP3A4 (Dina and Jafari, 2000)
and active efflux transporter activity (Soldner et al.,
2000). Transdermal delivery can be used to solve oral
bioavailability problem (Tanner and Marks, 2008).
Unfortunately, only few drugs can permeate through the
skin due to the high resistance of stratum corneum. The
epidermis, especially the outermost layer, the stratum
corneum, consists of the nearly solid dead cell which is
very difficult to be penetrated. The intercellular region of
such dead cell comprises of lipid in lamellar organization
(Bouwstra, Gooris, and Ponec, 2008). Such situation is
an ideal barrier for many substances to be delivered via
transdermal (Haftek, 2014). However, application of
chemical enhancer can be developed to solve the barrier
properties of skin (Paudel et al., 2010).
Vashisth and coworkers reported the potential chemical
enhancer for transdermal delivery of losartan, such as tea
tree oil, cumin oil, rose oil, and Aloe vera oil (Vashisth

et al., 2014). Capsaicin also can be used as enhancer of
losartan from transdermal patch dosage form (Petkar and
Kuchekar, 2007). The usage of proniosome carrier for
losartan transdermal delivery also enhances the rate of
losartan permeation across the skin (Thakur et al., 2009).
Oleic acid is an enhancer which is frequently used. It has
been proved that oleic acid can enhance skin permeation
of many compounds i.e. piroxicam (Park et al., 2005),
fisostigmin (Meshulam et al., 1993), and retinoid
(Moghimi, Noorani, and Zarghi, 2010), both in in vitro as
well as in vivo observation. Such enhancement activity
is mediated by combination of two mechanisms: lipid
fluidization and lipid phase separation. The intercalation
of cis-structure oleic acid into lipid lamellar of stratum
corneum induces the lipid disordering resulting the
fluidity enhancement similar to the effect of temperature
increasing. Additionally, oleic acid application can
extract the lipid stratum corneum and decrease the
membrane thickness (Naik, Pechtold, and Potts, 1995).
In the development of transdermal drug delivery, in
vitro evaluation should be followed by an in vivo
experiment to evaluate the efficiency of such delivery
system. Prediction of in vivo results is required as an
effort to select a system in the case of many formulation
showing distinctive advantages regarding in vitro data of
steady state flux and lag time diffusion. Some research
conducted the prediction of in vivo data based on in
vitro observation using exclusive software. Nakamura
and coworkers for instance, succeeded to predict the
tulobuterol pharmacokinetics profile from transdermal
delivery based on in vitro observation using SKIN CAD
software (Nakamura, Mori, and Tojo, 2012).
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This research was aimed to enhance losartan in vitro skin
permeation using oleic acid pretreatment, and use such
data, in particular the most frequent parameters calculated
in in vitro transdermal experiment, i.e. steady state flux
and lag time diffusion to predict the pharmacokinetics
profile. The prediction was constructed uncomplicatedly
using equation derived from intra venous infusion
equation and could be calculated easily using wellknown office software.
METHODS
Instrumentation and Material
In vitro observation was conducted using vertical type
diffusion cell (Figure 1) produced by Material Process
Laboratory, Department of Engineering Physics, The
Bandung Institute of Technology, with fresh male Wistar
rat skin as membrane. The rats were purchased from
Animal Handling Laboratory, Faculty of Pharmacy,
Gadjah Mada University, Yogyakarta. By controlling
the rat age (2 months) and weight (about 200 g),
it was assumed that all membranes have the same
thickness. Potassium losartan as active compound was
purchased from PT Kalbe Farma Jakarta. Oleic acid as
chemical enhancer (E Merk) was purchased from Asia
Lab Yogyakarta. Losartan concentration in receptor
compartment (calculated as potassium losartan) was
measured according previous research (Binarjo and
Nugroho, 2013). Briefly, HPLC (Shimadzu) controlled
using LC Solution software (Shimadzu) was equipped
with C-18 (Lichrospher RP 18 250-4 (5 µm)) as stationary
phase and UV detector set up at 223 nm. Acetonitrileacetic buffer pH 4 in a volume ratio of 3:2 was used as
mobile phase in an isocratic rate of 0.75 mL/minute.
The medium used for preparing drug formulation
was 0.05 M citric buffer pH 5.0 (contain citric acid
0.37 g/L, sodium citric 0.96 g/L, sodium chloride 4
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g/L; and mannitol 2 g/L). Propylene glycol was used
as solubilizing agent in a concentration of 15%. As
acceptor medium, 0.15 M phosphate buffer saline (PBS)
pH 7.4 (contains NaCl 8 g/l, Na2HPO4 2.86 g/L, KH2PO4
0.2 g/L, and KCl 0.19 g/mL) was used. All substances
used as mobile phase, acceptor medium as well as drug
solution were produced by E Merk and were purchased
from Asia Lab Yogyakarta.
Methods
Formulation of potassium losartan solution
In a 5 mL of volumetric flask, potassium losartan weighed
accurately was filled in to get a concentration as listed in
Table 1. About 0.75 mL of propylene glycol was added
and followed by dissolving the drug using ultrasonicator.
Citric buffer was added to get 5 mL drug solution.
Transdermal transport observation
The male Wistar rat skin was excised after being sacrificed
by introduced in chloroform saturated chamber. The hair
was cut off by electric clipper, and the fat was removed.
This clean skin was set up in the vertical diffusion cell
(Figure 1) followed by receptor compartment filling in
with PBS pH 7.4 and immersing magnetic bar prior to set
up on thermoline (Cimarec). For formulation I and III the
transports were started by filling the donor compartment
with 2 ml formulation. For formulation II and IV, as
listed in Table 1, the donor compartment was filled with
1 mL of oleic acid as a pretreatment. The magnetic bar
was stirred and the temperature was maintained at 35OC.
After pretreatment of formulation II and IV, the oleic acid
was removed, and the skin was cleaned three times using
distilled water. The water trace was absorbed by filter
paper prior to transport started. The transport was begun
by filling the donor compartment with 2 ml formulation.
The aliquot volume of 1.0 mL was withdrawn from
receptor compartment in scheduled time (0 (blank), 15,

Figure 1. Schematic representation of vertical type difusion cell
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Table 1. Concentration of potassium losartan and the pretreatment
Group (Formulation)
I
II
III
IV

Concentration of
Potassium Losartan
(mg/mL)
2
2
10
10

Oleic Acid Pretreatment
Without pretreatment
1 hour pretreatment
Without pretreatment
1 hour pretreatment

Table 2. Losartan transdermal transport parameters in mean + SD (n=3). Flux, lag time, permeability,
diffusion coefficient, partition coefficient and transport efficiency are symbolized
by J, Tlag, P, D, K and E respectively
Group
I
II
III
IV

J
(ng/(hour xcm2)
679.93+534.49
347.12+147.5
610.34+79.88
12849.98+4206.0

Tlag
(hour)
17.02+0.41
15.04+3.75
14.18+2.44
13.22+3.19

Px104
(cm/hour)
3.3+1.0
1.7+0.8
0.6+0.1
12.8+4.2

20, 22, 24, 26, 28, and 30 hours), and the fresh receptor
solution was added to maintain the constant volume of
receptor compartment. The concentration of losartan
(as potassium losartan) was measured using HPLC.
Chromatograms of Potassium losartan solution in PBS in
the range of concentration (ng/ml) 20.26, 50.65, 101.13,
202.26, 506.5, 1013, 2532.5, 5065, 10130, 20260 were
recorded. The peak area at the retention time about 9
minutes has strong correlation against concentration.
This concentration determination method has been
validated (Binarjo and Nugroho, 2013).
Data analysis
Transport profile was analyzed using Lag Time Diffusion
method. The transport parameters revealed from this
method are steady state flux (J) and lag time (tlag).
Permeability (P) was calculated (P=J/Cd) whereas Cd is
concentration of drug in donor compartment. Diffusion
coefficient (D) was calculated using the thickness of
membrane (h) and tlag (D=h2/6tlag). The data of P, D, and
h were used to calculate partition coefficient (K) (K=
hP/D) (Martin, Bustamante, and Chun, 1993). Transport
efficiency (E) was defined as a ratio of drug permeated
after 30 hours of transport (MT) to available drug in donor
compartment (MD). Statistical analysis independent
sample t-test was carried out using software SPSS 11.5,
(SPSS Inc, 2002). The difference is said to be significant
if the critical p-value is less than 0.05.
RESULTS AND DISCUSSION
Calibration curve of potassium losartan in PBS pH
7.4
Calibration curve of potassium losartan in PBS pH 7.4

Dx104
(cm2/hour)
3.9+2.6
4.7+1.3
4.8+0.9
5.2+1.2

K

E x103

0.171+0.055
0.069+0.011
0.026+0.007
0.525+0.285

2.7+0.2
2.3+1.7
0.8+0.1
18.7+5.0

is shown in Figure 2. It is shown that this curve has
strong linearity and can be used to calculate potassium
losartan concentration since calculated r is higher than r
table (0.95) (Muth 1999).
Transdermal transport profile
Figure 3 shows that the steady state condition has been
reached after 15 hours of transport for all formulation.
During 30 hours of experiment, there was not any post
steady state signal detected. Therefore, the transport
parameters were calculated from 15th to 30th hours of this
profile and the data is listed in Table 2.
Based on independent sample t-test (SPSS 11.5 version),
there was not any difference between steady state
flux group I and III (p>0.05), it means that losartan
concentration in donor compartment did not influence
the flux of transport without oleic acid pretreatment.
This results was not agree with first Fick’s law (Martin,
Bustamante, and Chun, 1993). It is postulated that the
higher of drug concentration in donor compartment would
always enhance the rate of transport, but the transport
efficiency would be decreased (Wester and Maibach,
1976). In present research, the rate of transport was not
increased while the transport efficiency was decreased.
The transport rate which was not increased by the
enhancement of drug concentration in donor compartment
can be explained base on the hydrophilicity of permeant
and the route of transdermal penetration. Showing the
pKa value of 3.64 (Meloun, Syrový, and Vrána, 2005),
based on Handerson-Hasselbach equation the losartan
solution at pH 5.0 is more than 90% dissociated resulting
in the low partition coefficient. As a result, the main
E-ISSN 2477-0612
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Figure 2. Calibration curve of potasium losartan in PBS pH 7.4.
The linear equation is y = 0.7013x – 2.4466 with r = 0.999991

Figure 3. Losartan transdermal transport profile The transport parameters are shown in
table 2. (based on 3 replicates, I: standard deviation (SD).
route of transdermal permeation is transappendageal via
hydrophilic route of sweat pore (Binarjo, 2014). The
very small number and very little area of sweat pore
was likely limited the number of permeant to cross over.
Therefore, increasing the number of permeant, i.e. donor
concentration, did not give any significant enhancement
of absorption rate.
The oleic acid pretreatment increased the transport
efficiency, resulting in the enhancement of steady state
flux of group IV in comparison to group III by 21-fold.
The ability of oleic acid to reduce the decreasing of
transport efficiency in the higher concentration was also
shown by the fact that in the low donor concentration, the
oleic acid pretreatment did not enhance the flux (group I
vs group II). Moreover, it was known that this transport
efficiency enhancement in high drug concentration of
donor solution was facilitated by the enhancement of
E-ISSN 2477-0612

partition coefficient by 20-fold, resulting in the change
of main route of permeation from transappendageal to
intercellular route.
The diffusion coefficient which was not increased
indicated that the lipid fluidization mechanism (Naik
et al., 1995) was not appeared. If the lipid fluidization
mechanism is occurred, based on Stoke-Einstein
equation, D=RT/(6лηrN), the diffusion coefficient will
be increased (Achuthan et al., 2011). Lipid fluidization
mechanism decreases the viscosity (η) of membrane, and
based on that equation above, the diffusion coefficient
will increase.
In vivo prediction
The in vivo prediction of transdermal delivery was
started by calculating the appropriate area of application
to reach the desired plasma level in the therapeutics
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Figure 4. The prediction of losartan pharmacokinetics profile achieved from transdermal
delivery, with oleic acid pretreatment (__) and without oleic acid pretreatment (---)

Figure 5. The movement of drug across the skin in in vitro observation (A) and in vivo study (B)
windows. Since the rate of drug entering to the body
(rate in) is equivalent to the rate of elimination (rate
out), the plasma level in desired level will be constant,
similar to intra vena infusion administration. The rate
in of delivery is the total flux (JT=J*A), while the rate
out is the zero order rate of elimination (k0=Cp*Vd*k).
The symbol of J, A, Cp, Vd, and k represent steady state
flux, surface area of application, desired plasma level in
therapeutics window, distribution volume, and first order
constant of drug elimination respectively.
Unfortunately, the effective plasma level of losartan has
not been defined yet clearly, because its metabolite also
has an antihypertensive activity (Choi et al., 2009). Lee
and coworkers plotted the pharmacokinetics profile of
losartan. By assuming the activity of losartan appear at 1
hour after administration, based on the pharmacokinetics
profile the plasma level of losartan (Cp) was 10 ng/mL.
This work also suggested that the value of k is 0.21 hr-1
(Lee et al., 2003). The Vd of losartan is 32 L (Lacy,
Armstrong, and Ingrim 1998). Using these data, the
application of formulation in group IV (flux=12849.98
ng cm-2 hr-1) required an area of 5.56 cm2 (a square with
the side of 2.36 cm) to reach the desired plasma level of
10 ng/ml. This area is reasonable in topical application.
The pharmacokinetics profile of transdermal delivery can

be predicted from in vitro data, which is analyzed using
lag time diffusion method resulting lag time and flux.
Cp as a function of application time can be calculated
based on the equation of intra vena infusion as shown
in equation 1.

The symbol of R represents the rate of delivery of intra
vena infusion (in ng/hour) which is similar with total
flux in transdermal delivery. The physical properties of
the skin require the lag time in transdermal transport
(delivery). This condition suggests the derivation of
equation 1 to equation 2, to be applicable for transdermal
delivery.

Pharmacokinetics profile can be predicted using equation
2. For the application of formulation in group IV, the
pharmacokinetics profile prediction is shown in figure 4,
by using the total flux (Jtotal) and lag time (tlag) are 71445.9
ng/hr (calculated from 12849.98 ng hr-1cm-2*5.56 cm2)
and 13.22 hours respectively.
Figure 4 indicates that the drug occurs in the blood after
10 hours of administration. The plateau condition which
E-ISSN 2477-0612
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was started at about 30 hours happened because the
constant rate in absorption (zero order) was equal to the
rate constant of elimination. The first order of elimination
is prompted to zero order because of the constant of
plasma level. It is predicted that 2 ml of dosage form
can be administrated for 48 hours in the constant of rate
absorption. Such time is reasonable since for 48 hours of
application, the drug absorbed was 3.43 mg (calculated
from 71445.9 ng/h x48 h), while the available drug in
dosage form was 20 mg (calculated from 10 mg/ml x
2mL).
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